Verastem (VSTM) Cash & Equivalents (2011 - 2026)

Verastem's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $165.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 40.81% year-over-year to $165.6 million; the TTM figure through Mar 2026 stood at $165.6 million (up 40.81% YoY), while the FY2025 annual figure was $205.0 million, up 130.8% from the prior year.
• Cash & Equivalents was $165.6 million for Q1 2026 at Verastem, down from $205.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $205.0 million in Q4 2025 to a low of $46.7 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $110.5 million across 5 years, with a median of $95.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents jumped 221.49% in 2022, then slumped 54.46% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $79.1 million in 2022, then decreased by 1.48% to $77.9 million in 2023, then climbed by 14.0% to $88.8 million in 2024, then soared by 130.8% to $205.0 million in 2025, then retreated by 19.24% to $165.6 million in 2026.
• The last three Cash & Equivalents figures came in at $165.6 million (Q1 2026), $205.0 million (Q4 2025), and $137.7 million (Q3 2025), per Business Quant data.